Download MendeleyDiscovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
Schroeder, G.M., An, Y., Cai, Z.W., Chen, X.T., Clark, C., Cornelius, L.A., Dai, J., Gullo-Brown, J., Gupta, A., Henley, B., Hunt, J.T., Jeyaseelan, R., Kamath, A., Kim, K., Lippy, J., Lombardo, L.J., Manne, V., Oppenheimer, S., Sack, J.S., Schmidt, R.J., Shen, G., Stefanski, K., Tokarski, J.S., Trainor, G.L., Wautlet, B.S., Wei, D., Williams, D.K., Zhang, Y., Zhang, Y., Fargnoli, J., Borzilleri, R.M.(2009) J Med Chem 52: 1251-1254
- PubMed: 19260711
- DOI: https://doi.org/10.1021/jm801586s
- Primary Citation of Related Structures:
3F82 - PubMed Abstract:
Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors. Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aqueous solubility and kinase selectivity. Analogue 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration. Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclinical safety profiles, 10 has been advanced into phase I clinical trials.
Organizational Affiliation:
Bristol-Myers Squibb Research and Development, Princeton, New Jersey, 08543-4000, USA. gretchen.schroeder@bms.com
